Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

54 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Novel endoscopic scoring system for immune mediated colitis: a multicenter retrospective study of 674 patients.
Wang Y, Abu-Sbeih H, Tang T, Shatila M, Faleck D, Harris J, Dougan M, Olsson-Brown A, Johnson DB, Shi C, Grivas P, Diamantopoulos L, Owen DH, Cassol C, Arnold CA, Warner DE, Alva A, Powell N, Ibraheim H, De Toni EN, Philipp AB, Philpott J, Sleiman J, Lythgoe M, Daniels E, Sandhu S, Weppler AM, Buckle A, Pinato DJ, Thomas A, Qiao W. Wang Y, et al. Among authors: faleck d. Gastrointest Endosc. 2024 Aug;100(2):273-282.e4. doi: 10.1016/j.gie.2024.01.024. Epub 2024 Jan 23. Gastrointest Endosc. 2024. PMID: 38272276
Response to Goyal and Katner.
Faleck DM, Freedberg DE. Faleck DM, et al. Am J Gastroenterol. 2017 May;112(5):806. doi: 10.1038/ajg.2017.65. Am J Gastroenterol. 2017. PMID: 28469222 No abstract available.
Correction: Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium.
Narula N, Peerani F, Meserve J, Kochhar G, Chaudrey K, Hartke J, Chilukuri P, Koliani-Pace J, Winters A, Katta L, Shmidt E, Hirten R, Faleck D, Parikh MP, Whitehead D, Boland BS, Singh S, Sagi SV, Fischer M, Chang S, Barocas M, Luo M, Lasch K, Bohm M, Lukin D, Sultan K, Swaminath A, Hudesman D, Gupta N, Shen B, Kane S, Loftus EV, Siegel CA, Sands BE, Colombel JF, Sandborn WJ, Dulai PS. Narula N, et al. Among authors: faleck d. Am J Gastroenterol. 2018 Dec;113(12):696. doi: 10.1038/s41395-018-0401-4. Am J Gastroenterol. 2018. PMID: 30390030 Free PMC article.
Enterocolitis due to immune checkpoint inhibitors: a systematic review.
Soularue E, Lepage P, Colombel JF, Coutzac C, Faleck D, Marthey L, Collins M, Chaput N, Robert C, Carbonnel F. Soularue E, et al. Among authors: faleck d. Gut. 2018 Nov;67(11):2056-2067. doi: 10.1136/gutjnl-2018-316948. Epub 2018 Aug 21. Gut. 2018. PMID: 30131322 Review.
Changes in Vedolizumab Utilization Across US Academic Centers and Community Practice Are Associated With Improved Effectiveness and Disease Outcomes.
Koliani-Pace JL, Singh S, Luo M, Hirten R, Aniwan S, Kochhar G, Chang S, Lukin D, Gao Y, Bohm M, Swaminath A, Gupta N, Shmidt E, Meserve J, Winters A, Chablaney S, Faleck DM, Yang J, Huang Z, Boland BS, Shashi P, Weiss A, Hudesman D, Varma S, Fischer M, Sultan K, Shen B, Kane S, Loftus EV, Sands BE, Colombel JF, Sandborn WJ, Lasch K, Siegel CA, Dulai PS. Koliani-Pace JL, et al. Among authors: faleck dm. Inflamm Bowel Dis. 2019 Oct 18;25(11):1854-1861. doi: 10.1093/ibd/izz071. Inflamm Bowel Dis. 2019. PMID: 31050734 Free PMC article.
Immune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel Disease.
Abu-Sbeih H, Faleck DM, Ricciuti B, Mendelsohn RB, Naqash AR, Cohen JV, Sellers MC, Balaji A, Ben-Betzalel G, Hajir I, Zhang J, Awad MM, Leonardi GC, Johnson DB, Pinato DJ, Owen DH, Weiss SA, Lamberti G, Lythgoe MP, Manuzzi L, Arnold C, Qiao W, Naidoo J, Markel G, Powell N, Yeung SJ, Sharon E, Dougan M, Wang Y. Abu-Sbeih H, et al. J Clin Oncol. 2020 Feb 20;38(6):576-583. doi: 10.1200/JCO.19.01674. Epub 2019 Dec 4. J Clin Oncol. 2020. PMID: 31800340 Free PMC article.
Reply to Y. Inagaki et al.
Abu-Sbeih H, Faleck DM, Dougan M, Wang Y. Abu-Sbeih H, et al. J Clin Oncol. 2020 May 20;38(15):1749-1750. doi: 10.1200/JCO.20.00295. Epub 2020 Apr 6. J Clin Oncol. 2020. PMID: 32250720 No abstract available.
Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer: a two-center observational study.
Zou F, Faleck D, Thomas A, Harris J, Satish D, Wang X, Charabaty A, Ernstoff MS, Glitza Oliva IC, Hanauer S, McQuade J, Obeid M, Shah A, Richards DM, Sharon E, Wolchok J, Thompson J, Wang Y. Zou F, et al. Among authors: faleck d. J Immunother Cancer. 2021 Nov;9(11):e003277. doi: 10.1136/jitc-2021-003277. J Immunother Cancer. 2021. PMID: 34789551 Free PMC article.
54 results